JPMorgan Chase & Co. Stock
JPMorgan Chase & Co. Stock
Pros and Cons of JPMorgan Chase & Co. in the next few years
Pros
Cons
Performance of JPMorgan Chase & Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| JPMorgan Chase & Co. | 0.620% | 1.048% | -4.313% | 16.578% | -9.265% | 112.746% | 89.465% |
| Huntington Bancshares Inc. | -0.990% | -2.368% | -13.188% | -2.224% | -11.605% | 36.000% | -4.406% |
| Wells Fargo & Co. | 0.760% | -0.346% | -11.763% | 1.984% | -17.627% | 87.343% | 94.116% |
| Citizens Financial | 0.020% | -2.287% | -10.556% | 31.859% | -1.781% | 69.024% | 29.882% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.JPMorgan Chase & Co. demonstrates a strong financial position as of the 2024 annual report. Key findings include: - Revenue increased to $177.556 billion from $158.104 billion in 2023 - Net income rose to $58.471 billion from $49.552 billion in 2023 - Strong profitability with a net margin of 6.56% - The overall financial trend appears positive, driven by revenue growth and improved profitability
Investors should carefully consider these factors when evaluating JPMorgan Chase & Co., weighing the company's strong profitability and diversified business model against its high leverage and market risk exposure.
Comments
News
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
A significant price target boost from an analyst at a prominent U.S. bank was the main catalyst behind Edgewise Therapeutics' (NASDAQ: EWTX) rise on the stock market on Tuesday. Investors were
Bargain Alert: Wells Fargo and Goldman Sachs Look Deeply Oversold
Financial stocks have faced a difficult stretch in recent weeks. Rising geopolitical tensions have rattled global markets and pushed investors toward safer assets, while concerns about the
Why I'm Not Buying JPMorgan Equity Premium Income ETF (But Maybe You Should)
You've probably read countless articles telling you that a particular stock, exchange-traded fund, or other investment is a great buy. But with most investments, the answer isn't so clear. For some